Richard Scolyer: Beloved Aussie Doctor Who Underwent World-First Brain Tumour Treatment Dies

Professor Richard Scolyer, a renowned melanoma researcher and former Australian of the Year, died on June 7, 2026, at age 59. According to ABC News and The Guardian, Scolyer used his own glioblastoma diagnosis to fast-track an experimental immunotherapy treatment, providing critical data for a cancer type that has seen few advances in 20 years.

Scolyer was a leading melanoma pathologist who spent his career improving cancer outcomes. When he was diagnosed with inoperable brain cancer in 2023, he chose to apply his professional expertise to his own condition. He became “patient zero” for an experimental approach that adapted existing melanoma fighting techniques for use against brain tumours, according to ABC News.

How did Professor Scolyer’s experimental treatment work?

The treatment focused on immunotherapy, a method of stimulating the body’s own immune system to recognize and destroy cancer cells. Scolyer and his colleagues took the principles they had developed for treating melanoma and adapted them to target glioblastoma. This specific type of brain cancer is notoriously difficult to treat because of the blood-brain barrier and the immunosuppressive environment of the brain.

By treating himself, Scolyer aimed to generate immediate, valuable data on whether these adapted therapies could penetrate the brain and trigger an immune response. ABC News reported that this work provided evidence on how immunotherapy could be utilized for brain cancers, a field that had experienced very few therapeutic breakthroughs for nearly two decades.

What were the outcomes of the trial?

The experimental treatment significantly extended Scolyer’s life beyond his initial medical expectations. Upon diagnosis, he was handed a prognosis of six months to one year. However, the trial treatment kept his cancer at bay for 22 months, according to ABC News.

The glioblastoma eventually returned in March 2025. Despite the recurrence, the data gathered during those 22 months offers a framework for future clinical trials. The results demonstrate that the “think big” approach to immunotherapy can be applied to aggressive brain tumours that were previously considered untreatable.

“I hope this has the power to transform how we treat all cancers, to think big and be courageous.”

Professor Richard Scolyer via ABC News

Why is this significant for brain cancer research?

Glioblastoma is one of the most aggressive forms of cancer. While immunotherapy has revolutionized the treatment of melanoma—turning a once-fatal diagnosis into a manageable or curable condition for many—similar success had not been replicated in neuro-oncology. The gap in progress was largely due to the unique biological defenses of the brain.

Scolyer’s decision to use himself as a test subject bypassed some of the traditional delays in early-phase research. By documenting his own response to the adapted melanoma therapy, he provided a proof-of-concept that immunotherapy can be effective in the brain. This contrast between the stagnation of brain cancer treatment and the rapid evolution of melanoma therapy was the primary driver of his experimental approach.

His legacy includes not only the data produced from his own case but also his broader contributions as a scientist. He is remembered as a researcher who worked tirelessly for Australians and sought to push the boundaries of what is possible in oncology, according to reports from the Daily Telegraph Sydney and the Sydney Morning Herald.